| Autor: |
Hadler SC; Surveillance, Investigations, and Research Branch, Centers for Disease Control, Atlanta, GA 30333., Alcala de Monzon M, Rivero D, Perez M, Bracho A, Fields H |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of epidemiology [Am J Epidemiol] 1992 Dec 15; Vol. 136 (12), pp. 1507-16. |
| DOI: |
10.1093/oxfordjournals.aje.a116472 |
| Abstrakt: |
To define better the epidemiology and clinical impact of hepatitis delta virus (HDV) infection among hepatitis B virus (HBV) carriers in less developed countries, the authors prospectively studied a cohort of 216 Yucpa Indian HBV carriers in Venezuela. HBV carriers were followed regularly between 1983 and 1988 by physical examination, laboratory testing for liver enzymes and HBV and HDV markers, and epidemiologic history. Among the cohort, 74 (34%) were initially positive for HDV infection, and 35 additional persons became infected during the study. Risk factors for new HDV infection included living in southern Yucpa villages; being young adults (15-19 years) or young children (1-9 years), and living in a household with a person with acute HDV infection. Persons with HDV infection were at high risk of developing chronic liver disease; 56% of HDV-infected persons had moderate-to-severe chronic liver disease at the end of the study compared with none of the HBV carriers without HDV infection. Mortality rates were 6.9% and 8.8% per year, respectively, among initially HDV-positive HBV carriers and those with new HDV infection, because of rapidly progressive chronic liver disease and fulminant hepatitis; mortality was significantly lower in HBV carriers without HDV infection and in non-HBV carriers. HDV superinfection is a devastating disease in HBV carriers in tropical South America. Prevention of HBV infection with hepatitis B vaccine is the best available tool to reduce the impact of this problem. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
